Trust Project

Vaccination against COVID-19 It reduces the risk of developing a severe form of the disease by 90% among those over 50 and also appears effective against the Delta variant, according to an extensive study conducted in France.

SIGHT: AstraZeneca Experimental Drug Reduces Severe COVID-19 Cases or Death by 67%

“People vaccinated are 9 times less likely to be hospitalized or die for COVID-19 than those not vaccinated ”, explained to AFP the epidemiologist Mahmoud Zureik, director of the Epi-Phare structure, which associates Assurance maladie (Cnam) with the Medicines Agency (ANSM), in charge of preparing the report.

These data, obtained from 22 million cases, confirm the conclusions of other studies carried out in Israel, the United Kingdom or the United States.

SIGHT: Molnupiravir | What You Should Know About MSD’s COVID-19 Pill

But the French report is “The widest fact in the world”, Zureik stressed.

The researchers compared the situation of 11 million vaccinated people over 50 years of age with another 11 million unvaccinated people of the same age group between December 27, 2020 (when vaccinations began in France) and July 20. .

SIGHT: Medicines against COVID-19, by Elmer Huerta

Two weeks after injecting the second dose, the scientists observed “A decrease in the risk of hospital admission of more than 90%.”

Insufficient data on Delta variant

The report’s authors also analyzed the eefficacy of the vaccines with respect to the Delta variant, originated in India and is currently dominant in the world.

SIGHT: Ivermectin: How Fake Science Invented a “Miracle” Drug Against COVID-19

To do this, they used data from just one month, between June 20 and July 20.

According to this information, they observed an efficacy of 84% among those older than 75 years and 92% among those 50-74 years.

Nevertheless, this period is too short to evaluate the real impact of vaccination on this variant “Zureik acknowledged.

“The study will continue to include data for August and September”, added.

This verification of the efficacy of the vaccines occurs both with the injections with Pfizer / BioNtech, AstraZeneca and Moderna. The first two are used in the immunization campaign against COVID-19 in Peru.

Janssen’s immunizing substance is the fourth licensed in France, but it was injected into so many people that it was not included in the study.

“This decrease is on the same level as the risk of dying during a COVID-19 hospitalization,” Epi-Phare indicated.

In addition, the efficacy on severe forms of the disease “not seem decrease over the period studied, five months ”.

“An epidemic without serious forms”

The study is divided into two parts: one on people over 75 years old (7.2 million cases analyzed) and another on people 50-74 years old (15.4 million cases).

The vaccination campaign in France began on December 27 for the first age group and between February 19 and May 10 for the second.

The study looked at these two age ranges through July 20, with similar efficacy results.

To compare hospitalization data, they matched a vaccinated person with an unvaccinated person of the same age, gender, and from the same region.

The report only looked at the risk of developing severe forms of coronavirus and he was not interested in the possibility of becoming infected and transmitting the virus.

Other studies had already shown that the Delta variant reduced the effectiveness of vaccines against the risk of contracting COVID-19.

The fact of avoiding serious forms is, however, “The main objective of public health”, Zureik stressed.

“An epidemic without serious forms is no longer an epidemic”, he assured.

According to the criteria of

Know more

RELATED VIDEO

Elmer Huerta explains the future of the pandemic
He assures that it will continue until 2022.

IT MAY INTEREST YOU:

Follow us on twitter:

Leave a Reply